<DOC>
	<DOCNO>NCT02935985</DOCNO>
	<brief_summary>The bio-markers substudy EsICH design recruit patient acute ( first 8h ) spontaneous intracerebral hemorrhage assess series biological parameter ( CBC , glucose , cholesterol , LDL cholesterol , triglyceride ) point-of-care bio-markers ( cTnI , hsCRP , D-Dimer ) order predict functional outcome patient determine input early risk stratification prognosis .</brief_summary>
	<brief_title>Tranexamic Acid Biomarkers Emergency Management Spontaneous Intracerebral Hemorrhage - Biomarkers Substudy</brief_title>
	<detailed_description>EsICH design multicenter double blind randomize ( 2:1 ) clinical trial assess effect tranexamic acid ( 2g total ) patient acute ( first 8h ) spontaneous intracerebral hemorrhage . The bio-markers substudy address category patient assess biological parameter ( CBC , glucose , cholesterol , LDL cholesterol , triglyceride ) point-of-care bio-markers ( cTnI , hsCRP , D-Dimer ) order predict functional outcome patient determine input early risk stratification prognosis . The patient diagnostic CT scan recruit Emergency Departments Neurology/ Neurosurgery Wards hospital enrol study blood sample draw first 8h onset condition . The patient clinically assess study investigator first 7 day admission second CT scan perform second day ( 24h onset condition ) . Telephone follow-ups complete day 90 180 coordinating center study . The bio-markers substudy observational , prospective multicenter ( study initially start one center - Cluj-Napoca - Tirgu Mures center activate . Two center might also include late time - Alba Bistrita-Nasaud , pending financial logistic reason ) .</detailed_description>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>1 . Age 18 year old 2 . CT scan diagnosis spontaneous intracerebral hemorrhage first 8h onset condition 3 . Informed consent 4 . Access telephone evaluation ( landline mobile phone participant family member ) 1 . GCS &lt; 8 point 2 . Secondary cause intracerebral hemorrhage ( trauma , know AVM , aneurysm , hemorrhagic transformation ischemic stroke , thrombosis central vein sinus , thrombolitic therapy , tumor , infection ) . 3 . Severe disability prior hemorrhagic event ( modify Rankin Score = &gt; 4 ) ; 4 . Known venous thrombembolic condition 5 . History coagulopathy ( genetic acquire ) 6 . Recent ischemic event ( &lt; 12 month ) ( ischemic stroke , myocardial infarction , peripheric artheriopathy ) 7 . History seizure ( present condition ) 8 . Undergoing treatment heparin , LMWH , GPIIb/IIIa antagonists oral anticoagulant ( warfarin/ acenocumarol , factor Xa inhibitor , thrombin inhibitor last 14 day ) 9 . Pregnancy breast feed 10 . Scheduled neurosurgical intervention next 24h 11 . Ongoing schedule hemostatic treatment prothrombin , vitamin K , fresh frozen plasma , platelets 12 . Enrollment clinical trial last 30 day 13 . Known terminal stage disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>spontaneous intracerebral hemorrhage</keyword>
	<keyword>point-of-care bio-markers</keyword>
	<keyword>multicenter</keyword>
	<keyword>Emergency Department</keyword>
	<keyword>Romania</keyword>
</DOC>